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Abstract
Background: Matrix-assisted laser desorption ionisation time of flight mass spectrometry (MALDI TOF-MS) allows the
identification of most bacteria and an increasing number of fungi. The potential for the highest clinical benefit of such
methods would be in severe acute infections that require prompt treatment adapted to the infecting species. Our objective
was to determine whether yeasts could be identified directly from a positive blood culture, avoiding the 1–3 days
subculture step currently required before any therapeutic adjustments can be made.
Methodology/Principal Findings: Using human blood spiked with Candida albicans to simulate blood cultures, we
optimized protocols to obtain MALDI TOF-MS fingerprints where signals from blood proteins are reduced. Simulated
cultures elaborated using a set of 12 strains belonging to 6 different species were then tested. Quantifiable spectral
differences in the 5000–7400 Da mass range allowed to discriminate between these species and to build a reference
database. The validation of the method and the statistical approach to spectral analysis were conducted using individual
simulated blood cultures of 36 additional strains (six for each species). Correct identification of the species of these strains
was obtained.
Conclusions/Significance: Direct MALDI TOF-MS analysis of aliquots from positive blood cultures allowed rapid and
accurate identification of the main Candida species, thus obviating the need for sub-culturing on specific media.
Subsequent to this proof-of-principle demonstration, the method can be extended to other clinically relevant yeast species,
and applied to an adequate number of clinical samples in order to establish its potential to improve antimicrobial
management of patients with fungemia.
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Introduction
Matrix-assisted laser desorption ionisation time of flight mass
spectrometry (MALDI TOF-MS) has been recently described as
an ‘‘ongoing revolution’’ because it allows rapid and accurate
identification of bacteria [1,2] and fungi [3,4,5]. Consequently, it
is fast becoming an important and increasingly widely available
tool in clinical microbiology laboratories. At present, accurate
identification of genus/species of the pathogenic fungi is only
performed on positive blood cultures grown from patient samples
for 24/48. An additional 24/48 hours period, during which
subcultures on specific media are grown, is required for the
identification of the causative pathogen. Any advances that would
shorten the time to correct diagnosis would be of some benefit to
clinical management.
In this manuscript we addressed this issue for Candida species,
which are one of the commonest etiological agents of invasive
fungal infections as well as of nosocomial bloodstream infections
[6]. Molecular-based methods developed recently can provide
presumptive identification of some fungal species (e.g. C. albicans or
C. glabrata) [7], or sensitive simultaneous detection and identifica-
tion of fungal pathogens directly from blood culture specimens [8].
However, these methods are costly. We sought to establish
whether specific molecular components found in Candida-positive
blood cultures, which we hypothesized would vary according to
the pathogen species present, could be exploited to provide rapid
species determination by MALDI TOF-MS. This would provide a
substantial reduction in the delay before initiation of or adjustment
to an effective therapy for invasive candidiasis. Although the costs
of MALDI TOF-MS might be considered high at first sight, the
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disciplinary laboratories [1,9]. Moreover, in our laboratory
running costs for sample handling and data analysis are slight
and lower than those of current biochemical identification
methods.
Here, we show that it was possible to identify a Candida species
by MALDI TOF-MS analysis of an aliquot from the positive blood
culture, which removes the need for further lengthy sub-culturing
on specific media. This would provide a clinically significant gain
of one to two days in the initiation of the most effective therapy.
Methods
Experimental and Clinical Samples and Ethics Statement
For blood culture simulation, Mycosis IC/F bottles (Becton-
Dickinson, France) were filled with blood of healthy volunteers
(Centre de Transfusion Sanguine). Inocula (100 mL) adjusted at
10
4 yeasts/ml in 0.9% sodium chloride were then inoculated into
each bottle (yeast was omitted for control tests). The bottles were
then incubated at 35uC with rocking agitation into a Bactec 9240
automat (Becton-Dickinson, France). Growth was continuously
and automatically monitored. Simulated blood cultures were
replicated to test reproducibility. For each blood culture bottle,
two samples were used as biological replicates. 48 Candida strains
obtained from ATCC or the Pitie ´-Salpe ˆtrie `re Hospital (PS) were
tested. These belong to 6 species (C. albicans, C. glabrata, C. krusei, C.
lusitaniae, C. parapsilosis and C. tropicalis) representing those most
frequently isolated from candidemia (Table 1). The Candida strains,
stored at 220uC in 10% glycerol, were cultured on CHROMagar
medium (Becton-Dickinson, Le Pont de Claix, France) for 48 h at
37uC before being inoculated into blood culture bottles. All the
strains tested in this work had been previously identified at the
species level using conventional method (API32C biochemical
panel, Biome ´rieux Lyon, France).
Following the development of our method, we had the
opportunity to test it on a positive blood culture originating from
a kidney transplant recipient who developed lymphoma in 2009
with a worsening condition. Cytotoxic chemotherapy was initiated
in June 2009 and the patient was aplastic 6 days later. Due to
unexplained fever, the patient was sampled for a set of two blood
cultures. One of these was positive after 24 hours of incubation for
fungus and C. albicans was identified 24 hours later with classical
techniques (culture on CHROMagar medium). Sample collection
from patient and further analyses were made in full accordance
with the tenets of the Declaration of Helsinki. We sought approval
for the use of the cultures derived from the blood collected from
the patient as part of medical care to the local Institutional Review
Board (CPP-Ile-de-France-VI, GH Pitie ´-Salpe ˆtrie `re). The IRB
trenched that in this particular case, formal IRB approval and
written consent from patients are not required (Art. L1121-1 of
Public Health code) given that medical care would not be modified
by the research process. Simulated blood cultures were carried out
with blood obtained within the framework of convention between
INSERM and French blood bank (EFS 093031-ABP). According
to this procedure, the donor provides a written agreement for the
use of donated blood for research purposes.
Sample Preparation for Proteomic Analysis
Once detected as positive by the Bactec 9240, 2 ml from the
blood culture bottle were sampled and centrifuged at 10,000 rpm
for 2 min at room temperature. The supernatant was discarded
and the pellet washed with 1.5 mL pure water. Following
centrifugation, the pellet was re-suspended in 1.5 mL of 0.1%
sodium dodecyl sulfate and incubated for 2 min. After centrifu-
gation, the resulting pellet was washed twice in 1.5 mL pure water,
centrifuged and suspended in 300 mL of pure water +900 mLo f
absolute ethanol. After centrifugation, 50 mL of 70% formic acid
+50 mL pure acetonitrile were added to the pellet and the
subsequent solution was thoroughly vortexed before a final
centrifugation and then tested. Because, initiation of methods for
identification is sometimes delayed, we also test our method by
analysing the profiles obtained following the storage of the positive
blood culture bottles for 24 hours at 4uC.
MALDI-TOF Mass Spectrometry Analysis
Sample preparation for MALDI TOF analysis has been
described elsewhere [3]. Briefly, supernatants were distributed
on a MALDI AnchorChip slide (Bruker-Daltonics, Bremen,
Germany) then air-dried and recovered by a-cyano-4-hydroxy-
cinnamic acid (CHCA) matrix (50 mg/ml in 50:50, acetoni-
trile:2.5% TFA). DH5a Escherichia coli protein extract was used for
external calibration.
MALDI-TOF analysis were performed on a Bruker Autoflex I
MALDI TOF mass spectrometer with a nitrogen laser (337 nm)
operating in linear mode with delayed extraction at 20 kV
accelerating voltage. Each spectrum was automatically collected
in the positive ion mode as an average of 700 laser shots (50 laser
shots at 14 different spot positions). A mass range between 3,000
and 20,000 m/z (ratio mass/charge) was selected to collect the
signals with the AutoXecute tool of flexcontrol acquisition software
(Version 2.4; Bruker-Daltonics). Only peaks with a signal/noise
ratio .3 were considered. Spectra were eligible for further analysis
when the peaks had a resolution better than 600. For each
bloodculture bottle, we collected mass spectra from 2 biological
replicates and 2 technical replicates.
Data
Pre-processing of the spectra was done using ClinproTool 2.2
software (Bruker Da, Gmbh, Bremen, Germany). Recalibration
was performed with base line subtraction. Peak picking (for
S/N.4) was performed using calculation of the total average
spectrum. Only peaks in the 5000–7400 Da mass range was
retained for statistical analysis.
Table 1. List of the Candida species and strains used in the
study.
Species Strains
Reference strains Strains used for validation
C. albicans PS 5441-3, ATCC90028 PS 4667; PS 544; PS 12372; PS 12355;
PS 11802; PS 11868, Patient 1: PS 7221
C. glabrata PS 5282, PS 5441-1 PS 569; PS 5282; PS 11188; PS 11189;
PS 11594; PS 11597
C. tropicalis PS 5441-2, PS 6325 PS 9359; PS 11185; PS 11186; PS 11187;
PS 11745; PS 10597
C. lusitaniae PS 5441-4, PS 6356 PS 5176; PS 9230; PS 922; PS 256;
PS 11242; PS 990
C. parapsilosis PS 6, ATCC22019 PS 9360; PS 12338; PS 12339; PS 12340;
PS 12341; PS 12342
C. krusei PS 6447, ATCC6258 PS 9395; PS 11190; PS 11191; PS 11192;
PS 11193; PS 11194
ATCC, American Type Culture Collection, Manassas, VA, USA. PS, Pitie ´-
Salpe ´trie `re Hospital, AP-HP, Paris, France. *used as reference strain for building
database in statistical analysis.
doi:10.1371/journal.pone.0008862.t001
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A spectra reference database was built containing seven classes,
one for each of the 6 Candida species tested plus the negative (yeast-
free) control. Each class was defined by the spectra collected from
two randomly selected strains from each species (Table 1). This
ability to determine the Candida species using this reference
database was then established using 6 additional strains for each of
the six Candida species under consideration (i.e. 36 additional
strains). Spectra (4 per strain) were then acquired for each of these
strains and then compared to the reference database in order to
ascribe each to one of the classes defined. The comparison was
based on a similarity measure as given by the mean of the
Spearman rank correlation coefficients between the spectra from
the unknown strain and those of the reference strains used
to construct the database: for each class, 8 rank correlation
coefficients were computed (between the 2 spectra from the
reference database and the 4 spectra from the unknown strain).
The mean of these coefficients is indicates the degree of similarity
between the unknown strain and each of the reference classes. The
species to which the unknown strain is considered to belong is the
one for which the best similarity was obtained. The algorithm used
to achieve this was implemented in a FORTRAN program written
by the authors and will be made available on request.
Results
We first wished to optimize samples extraction protocols, i.e.
to obtain spectra where contaminating blood components are
minimized to such an extent that they do not obscure spectral
peaks that are specific to fungal cultures. This was carried out
using the C. albicans susceptible reference strain, ATCC90028.
Optimal results were obtained from extraction done on 2 ml of
blood culture (detected as positive by the automat) and with SDS
0.1% as detergent.
We then analysed the mass spectrometry fingerprint patterns
obtained from aliquots from blood culture bottles inoculated with
one or other of two randomly chosen reference strains from each
of different Candida species: C. glabrata, C. krusei, C. lusitaniae, C.
parapsilosis and C. tropicalis (Table 1). Typical MALDI TOF-MS
spectra obtained from these simulated blood culture are presented
in Figure 1. As expected many masses were common to all
contaminated and control blood cultures, most probably repre-
senting haemoglobins and other blood components. Nonetheless,
detectable and quantifiable Candida-specific spectral differences
(gain or loss of mass) in the 5000–7400 Da mass range were noted
between the various yeast-inoculated blood cultures. Some peaks
were common to several species, for e.g. the 6903 Da in the
spectra of C. albicans, C. lusitaniae and C. tropicalis blood cultures,
while others were specific to each species. These observations were
consistently made in reproducibility experiment and for the two
strains from the same species. Using these spectra, a reference
database was obtained.
In order to ascribe to which species the spectra from a putative
clinical sample correspond, we devised a statistical approach based
on the mean Spearman rank correlation coefficient used as a
similarity measure between groups of spectra. We validated this
Figure 1. Alterations in the mass spectra (virtual gel) of blood cultures injected with different yeast strains. The x-axis represents Da
value, For each strain 4 spectra (numbered on the left Y-axis) from two biological replicates deposited twice on the spectrometer plate are presented.
A grey colour scale for peak intensity with arbitrary units is provided on the right y-axis. Each spectrum was automatically collected in the positive ion
mode as an average of 700 laser shots. Mass range 3,000–20,000 Da was selected with a signal/noise ratio .3 (S/N) and resolution better than 600
(Flexcontrol software 2.4; Bruker-Daltonics). The control sample was from a yeast-free blood culture.
doi:10.1371/journal.pone.0008862.g001
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Class
MS
identification
Conventional
identification**
Tested
strain C. albicans C. glabrata C. krusei C. lusitaniae C. parapsilosis C. tropicalis
Yeast free
control
PS 569 0.312 0.834 0.549 0.311 0.379 0.140 0.489 C. glabrata C. glabrata
PS 569* 0.366 0.582 0.510 0.352 0.422 0.178 0.428 C. glabrata C. glabrata
PS 11188 20.134 0.571 0.093 20.097 20.003 20.211 0.181 C. glabrata C. glabrata
PS 11189 0.203 0.724 0.334 0.244 0.254 0.108 0.348 C. glabrata C. glabrata
PS 11594 0.215 0.552 0.315 0.332 0.292 0.093 0.226 C. glabrata C. glabrata
PS 11597 0.337 0.659 0.473 0.442 0.384 0.184 0.445 C. glabrata C. glabrata
PS 5282 0.201 0.809 0.544 0.293 0.354 0.025 0.520 C. glabrata C. glabrata
PS 5176 0.398 0.167 0.357 0.644 0.348 0.290 0.247 C. lusitaniae C. lusitaniae
PS 5176* 0.395 0.222 0.428 0.525 0.407 0.299 0.321 C. lusitaniae C. lusitaniae
PS 922 0.415 0.044 0.075 0.509 0.083 0.129 0.050 C. lusitaniae C. lusitaniae
PS 9230 0.576 0.451 0.475 0.677 0.341 0.330 0.550 C. lusitaniae C. lusitaniae
PS 256 0.430 20.047 0.042 0.536 0.118 0.181 0.014 C. lusitaniae C. lusitaniae
PS 11242 0.526 0.316 0.337 0.691 0.291 0.324 0.336 C. lusitaniae C. lusitaniae
PS 990 0.378 20.119 0.026 0.531 0.137 0.146 20.069 C. lusitaniae C. lusitaniae
PS4667 0.751 0.466 0.502 0.615 0.326 0.401 0.614 C. albicans C. albicans
PS4667* 0.534 0.103 0.117 0.381 0.082 0.293 0.145 C. albicans C. albicans
PS 11802 0.768 0.486 0.524 0.730 0.544 0.523 0.566 C. albicans C. albicans
PS 11862 0.722 0.415 0.354 0.616 0.367 0.391 0.396 C. albicans C. albicans
PS 12355 0.419 0.022 20.059 0.252 20.030 0.238 20.016 C. albicans C. albicans
PS 12372 0.657 0.047 0.129 0.449 0.153 0.443 0.222 C. albicans C. albicans
PS 5441 0.506 0.127 0.128 0.450 0.153 0.287 0.126 C. albicans C. albicans
PS 9359 0.401 20.149 20.113 0.193 20.059 0.615 0.039 C. tropicalis C. tropicalis
PS 9359* 0.418 0.131 0.025 0.310 20.030 0.577 0.103 C. tropicalis C. tropicalis
PS 11185 0.460 0.082 0.079 0.350 0.093 0.674 0.217 C. tropicalis C. tropicalis
PS 11186 0.512 0.011 0.031 0.392 0.056 0.747 0.144 C. tropicalis C. tropicalis
PS 11187 0.410 20.104 20.067 0.263 20.039 0.637 0.050 C. tropicalis C. tropicalis
PS 11745 0.112 20.167 20.247 0.062 20.034 0.261 20.080 C. tropicalis C. tropicalis
PS 10597 20.014 20.543 20.588 20.201 20.314 0.024 20.392 C. tropicalis C. tropicalis
PS 9395 0.248 0.622 0.768 0.394 0.573 0.034 0.631 C. krusei C. krusei
PS 9395* 0.339 0.316 0.598 0.416 0.512 0.212 0.365 C. krusei C. krusei
PS 11190 0.204 0.106 0.351 0.341 0.308 0.088 0.043 C. krusei C. krusei
PS 11191 0.075 0.291 0.427 0.230 0.350 20.016 0.180 C. krusei C. krusei
PS 11192 0.169 0.390 0.557 0.317 0.488 0.083 0.326 C. krusei C. krusei
PS11194 20.033 0.138 0.309 0.048 0.308 20.083 0.098 C. krusei C. krusei
PS 11193 0.066 0.352 0.533 0.182 0.493 20.026 0.341 C. krusei C. krusei
PS 9360 0.204 0.323 0.626 0.340 0.657 20.030 0.409 C. parapsilosis C. parapsilosis
PS 9360* 0.310 0.408 0.678 0.462 0.751 0.121 0.459 C. parapsilosis C. parapsilosis
PS12338 0.207 0.300 0.654 0.254 0.760 0.059 0.435 C. parapsilosis C. parapsilosis
PS 12339 0.189 0.328 0.640 0.262 0.704 0.028 0.436 C. parapsilosis C. parapsilosis
PS 12340 0.168 0.253 0.591 0.216 0.689 0.030 0.399 C. parapsilosis C. parapsilosis
PS 12341 0.290 0.471 0.707 0.314 0.727 0.085 0.635 C. parapsilosis C. parapsilosis
PS 12342 0.148 0.309 0.616 0.167 0.742 20.041 0.390 C. parapsilosis C. parapsilosis
PS 7221 0.163 20.143 20.097 0.020 20.007 0.055 20.185 C. albicans C. albicans
*denotes results obtained from positive blood cultures that had been stored for 24 hours at 4uC prior to SDS extraction. ** See Methods paragraph. The best score is
presented in bold.
doi:10.1371/journal.pone.0008862.t002
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(from the inoculation step onwards) to six additional strains
(distinct from the reference strains) from each of the six species. As
shown in Table 2, the algorithm used led to the correct
identification of species of all the 36 additional strains tested.
For a subset of the strains (one for each Candida species), the
positive blood culture had been stored for 24 hours at 4uC before
extraction and MALDI TOF-MS analysis.
While we were finalizing the methodology a positive blood
culture from a patient admitted to the Pitie ´-Salpe ˆtrie `re Hospital
became available. MALDI TOF-MS analysis as described above
unambiguously identified C. albicans as the causal agent, which
concords with the identification afforded by routine methods for
blood culture.
Discussion
Candidemia, one of the most common nosocomial bloodstream
infection [6], is serious and life-threatening with overall and specific
mortality rates of 60 and 49%, respectively, a bleak prognosis that
rivals that of bacteraemia [10,11]. Five species (C. albicans, C. glabrata,
C. parapsilosis, C. tropicalis and C. krusei) account for 90% of cases.
Prompttreatmentwithanappropriateantifungaltherapy,whichwill
substantially improves prognosis [12], faces two obstacles. The
selection of an effective treatment of candidemia depends on the
infecting Candida species [6], of which more than twenty each with
different antifungals susceptibility profiles [13,14] are known. At
present, species determination requires from 2 to 5 days after
collection of the blood samples from the patient.
We present here a proof-of-concept validation of a method
based on MS analysis for the accurate and rapid identification of
Candida species one to two days after collection of the clinical blood
sample. This method can be complemented by a MALDI TOF-
MS drug susceptibility testing methodology that we have pre-
viously developed [15]. The main advantage combining these two
assays is the gain of one to two days in the initiation of the most
appropriate therapy for patients with a potentially lethal condition.
The genus Candida displays extensive genetic diversity and our
current database is not exhaustive. We are currently expanding it
to include not only other Candida spp isolated from human samples
but also others yeast (e.g. Cryptococcus spp., Trichosporon spp.) and
filamentous fungi such as Fusarium spp. We have initiated an
evaluation of MALDI TOF-MS fungus identification in a clinical
setting in order to establish its potential to substantially improve
the management of candidiasis through very early administration
of the most appropriate antifungal therapy. This will help to
reduce costs as well as to minimize the selection of drug-resistant
fungal pathogens.
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